FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735662223> ?p ?o ?g. }

• W2735662223 abstract "Delirium is a neurobehavioural disturbance that frequently develops particularly in the intensive care unit (ICU) population. It was first described more than half a century ago, where it was already discovered as a state that might come along with serious complications such as prolonged ICU and hospital stay, reduced quality of life and increased mortality. However, in most cases, there is still lack of proof for causal relationship. Its presence frequently remains unrecognised due to suggested predominance of the hypoactive form. Furthermore, in the general ICU population, it has been shown that the duration of delirium is associated with worse long-term cognitive function. Due to the multifactorial origin of delirium, we have several but no incontestable treatment options. Nonetheless, delirium bears a high burden for patient, family members and the medical care team.The Basel ProDex Study targets improvement of hyperactive and mixed delirium therapy in critically ill patients. We will focus on reducing the duration and severity of delirium by implementing dexmedetomidine into the treatment plan. Dexmedetomidine compared with other sedatives shows fewer side effects representing a better risk profile for delirium treatment in general. This could further contribute to higher patient safety.The aim of the BaProDex Trial is to assess the superiority of dexmedetomidine to propofol for treatment of hyperactive and mixed delirium in the ICU. We hypothesise that dexmedetomidine, compared with propofol administered at night, shortens both the duration and severity of delirium.The Basel ProDex Study is an investigator-initiated, one-institutional, two-centre randomised controlled clinical trial for the treatment of delirium with dexmedetomidine versus propofol in 316 critically ill patients suffering from hyperactive and mixed delirium. The primary outcome measure is delirium duration in hours. Secondary outcomes include delirium-free days at day 28, death at day 28, delirium severity, amount of ventilator days, amount of rescue sedation with haloperidol, length of ICU and hospital stay, and pharmaceutical economic analysis of the treatments. Sample size was estimated to be able to show the superiority of dexmedetomidine compared with propofol regarding the duration of delirium in hours. The trial will be externally monitored according to good clinical practice (GCP) requirements. There are no interim analyses planned for this trial.This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the International Conference on Harmonization- Good Clinical Practice (ICH-GCP) or Europäische Norm International Organization for Standardization (ISO EN 14155; as far as applicable) as well as all national legal and regulatory requirements. Only the study team will have access to trial specific data. Anonymisation will be achieved by a unique patient identification code. Trial data will be archived for a minimum of 10 years after study termination. We plan to publish the data in a major peer-reviewed clinical journal.ClinicalTrials.gov Identifier: NCT02807467 PROTOCOL VERSION: Clinical Study Protocol Version 2, 16.08.2016." @default.
• W2735662223 created "2017-07-21" @default.
• W2735662223 creator A5000457415 @default.
• W2735662223 creator A5002077006 @default.
• W2735662223 creator A5004819230 @default.
• W2735662223 creator A5042974849 @default.
• W2735662223 creator A5047479937 @default.
• W2735662223 creator A5060203378 @default.
• W2735662223 creator A5065590767 @default.
• W2735662223 creator A5068852858 @default.
• W2735662223 creator A5072992929 @default.
• W2735662223 creator A5080055102 @default.
• W2735662223 creator A5082719632 @default.
• W2735662223 date "2017-07-01" @default.
• W2735662223 modified "2023-10-13" @default.
• W2735662223 title "Comparison of propofol and dexmedetomidine infused overnight to treat hyperactive and mixed ICU delirium: a protocol for the Basel ProDex clinical trial" @default.
• W2735662223 cites W1537670670 @default.
• W2735662223 cites W1604355414 @default.
• W2735662223 cites W1965201247 @default.
• W2735662223 cites W1966853666 @default.
• W2735662223 cites W1967664978 @default.
• W2735662223 cites W1968069550 @default.
• W2735662223 cites W1977580466 @default.
• W2735662223 cites W1989203230 @default.
• W2735662223 cites W1996886405 @default.
• W2735662223 cites W1999285830 @default.
• W2735662223 cites W2000129134 @default.
• W2735662223 cites W2007909953 @default.
• W2735662223 cites W2021714808 @default.
• W2735662223 cites W2024476766 @default.
• W2735662223 cites W2025829561 @default.
• W2735662223 cites W2029469073 @default.
• W2735662223 cites W2032833970 @default.
• W2735662223 cites W2044636978 @default.
• W2735662223 cites W2047716792 @default.
• W2735662223 cites W2054290601 @default.
• W2735662223 cites W2058321608 @default.
• W2735662223 cites W2067929573 @default.
• W2735662223 cites W2073830685 @default.
• W2735662223 cites W2079916073 @default.
• W2735662223 cites W2085641231 @default.
• W2735662223 cites W2092902018 @default.
• W2735662223 cites W2096160952 @default.
• W2735662223 cites W2103493064 @default.
• W2735662223 cites W2103708182 @default.
• W2735662223 cites W2115415903 @default.
• W2735662223 cites W2124135067 @default.
• W2735662223 cites W2130271602 @default.
• W2735662223 cites W2135672238 @default.
• W2735662223 cites W2137904709 @default.
• W2735662223 cites W2138928595 @default.
• W2735662223 cites W2142118676 @default.
• W2735662223 cites W2143617649 @default.
• W2735662223 cites W2144249679 @default.
• W2735662223 cites W2147364251 @default.
• W2735662223 cites W2150225918 @default.
• W2735662223 cites W2150615416 @default.
• W2735662223 cites W2154459344 @default.
• W2735662223 cites W2170114191 @default.
• W2735662223 cites W2193064313 @default.
• W2735662223 cites W2204629581 @default.
• W2735662223 cites W2207459461 @default.
• W2735662223 cites W2301769892 @default.
• W2735662223 cites W2315643594 @default.
• W2735662223 cites W2315650055 @default.
• W2735662223 cites W2319886839 @default.
• W2735662223 cites W2397823964 @default.
• W2735662223 cites W2428004695 @default.
• W2735662223 cites W4248146214 @default.
• W2735662223 cites W4298872162 @default.
• W2735662223 doi "https://doi.org/10.1136/bmjopen-2016-015783" @default.
• W2735662223 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5726074" @default.
• W2735662223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28710219" @default.
• W2735662223 hasPublicationYear "2017" @default.
• W2735662223 type Work @default.
• W2735662223 sameAs 2735662223 @default.
• W2735662223 citedByCount "10" @default.
• W2735662223 countsByYear W27356622232018 @default.
• W2735662223 countsByYear W27356622232019 @default.
• W2735662223 countsByYear W27356622232020 @default.
• W2735662223 countsByYear W27356622232022 @default.
• W2735662223 crossrefType "journal-article" @default.
• W2735662223 hasAuthorship W2735662223A5000457415 @default.
• W2735662223 hasAuthorship W2735662223A5002077006 @default.
• W2735662223 hasAuthorship W2735662223A5004819230 @default.
• W2735662223 hasAuthorship W2735662223A5042974849 @default.
• W2735662223 hasAuthorship W2735662223A5047479937 @default.
• W2735662223 hasAuthorship W2735662223A5060203378 @default.
• W2735662223 hasAuthorship W2735662223A5065590767 @default.
• W2735662223 hasAuthorship W2735662223A5068852858 @default.
• W2735662223 hasAuthorship W2735662223A5072992929 @default.
• W2735662223 hasAuthorship W2735662223A5080055102 @default.
• W2735662223 hasAuthorship W2735662223A5082719632 @default.
• W2735662223 hasBestOaLocation W27356622231 @default.
• W2735662223 hasConcept C126322002 @default.
• W2735662223 hasConcept C168563851 @default.
• W2735662223 hasConcept C177713679 @default.
• W2735662223 hasConcept C194828623 @default.
• W2735662223 hasConcept C2776277131 @default.
• W2735662223 hasConcept C2776376669 @default.

• next